Phase III data from the Montreal Heart Institute suggests colchicine could serve as an oral alternative to IV-infused mAbs for COVID-19 in the outpatient setting, but more data are needed. The COLCORONA trial did not...

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...

Having helped create the fastest vaccine development programs in history, Moncef Slaoui has stepped down as scientific adviser and co-leader of Operation Warp Speed, the U.S. government’s initiative to develop, manufacture and distribute countermeasures to COVID-19. Slaoui and...

Led by GSK neuro R&D alumni and fueled by $100 million in series A funds, SciNeuro aims to develop  neurodegeneration and neuropsychiatric therapies for the Greater China market through a mix of partnering and in-house R&D....

After a record year for NASDAQ listings, a burgeoning queue of biopharmas seeking IPOs in 2021 swelled further late Tuesday as immuno-oncology companies Adagene and NexImmune filed for offerings. The pair joined seven therapeutics developers...

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it restructured in 2H19...

With a more sophisticated protocol for selecting patients and positive Phase II data in hand, Eli Lilly is heading into a confirmatory trial of its Alzheimer’s therapy donanemab in an arguably stronger...

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....

In the face of defeats in three federal courts, the Trump administration has abandoned its attempt to use an administrative shortcut to impose a “most favored nation” international reference pricing scheme on Medicare Part B...

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...